Close Menu

NEW YORK (360Dx) — Sienna Cancer Diagnostics said today that it has signed an agreement to evaluate its cancer hTERT in vitro diagnostic in thyroid cancer in collaboration with the Royal Melbourne Hospital (RMH) in Australia.

The test detects the hTERT component of telomerase, a biomarker that the company said is upregulated in about 85 percent of tissue-based cancers. Sienna currently markets the test as an aid in bladder cancer diagnosis alongside standard urine cytology testing.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.